Proceeds to support continued platform scaling, progress therapeutic leads toward preclinical proof of concept Sapreme, a biotechnology company focused on improving the delivery and efficacy
Sapreme Appoints Henrik Luessen as Chief Business Officer Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer. In this role, Dr. Luessen will advise Sapreme in its business development, partnerships and funding activities, and will report to Guy Hermans, Ph.D., Chief Executive Officer. Henrik brings strong experience with emerging biotechnology companies to Sapreme including licensing, portfolio strategy, financing and strategic development which are critical aspects for Sapreme at this stage of development,
commented Guy Hermans, Chief Executive Officer of Sapreme.